AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01098630 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Patients' medical record information is collected and staff complete the treatment review form
Study NCT01098630 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01650584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISTA Tears
Description: sterile ophthalmic solution
Study NCT01650584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Sterile ophthalmic solution
Study NCT05014841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Tasks
Description: Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
Study NCT01402635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: point-of-care chemistry test(POCT) (Piccolo)
Description: comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
Study NCT01402635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: point-of-care chemistry test(POCT) (Piccolo)
Description: comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
Study NCT04305353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary (blank journal) plus PTSD psycho-education
Description: A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
Study NCT04305353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTSD psycho-education alone
Description: We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015.
Study NCT04305353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PTSD psycho-education alone
Description: We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015.
Study NCT04075409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study NCT02318290 — intervention group
Intervention type: DRUG
Intervention: Opiates
Description: Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
Study NCT02580383 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency neurotomy of lumbar medial branch
Description: In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
Study NCT01243528 — intervention group
Intervention type: OTHER
Intervention: Laboratory values
Description: Laboratory values which represent nutritional status
Study NCT01180608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Spectroscopy
Description: During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)
Study NCT01180608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MR Spectroscopy
Description: During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)
Study NCT04590690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Special diet
Description: The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
Study NCT01256021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
Study NCT02426151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEPO-A
Description: BEPO-A (Bioreactor manufacturing process)
Study NCT02426151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REPO-A
Description: REPO-A (Roller bottle manufacturing process)
Study NCT03474081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
Study NCT03474081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
Study NCT03474081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
Study NCT03474081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FF/UMEC/VI
Description: Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
Study NCT03474081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match tiotropium
Description: Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
Study NCT03474081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA inhaler
Description: ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
Study NCT03474081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANDIHALER
Description: Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
Study NCT03474081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
Study NCT02077361 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1 vector
Description: No additional details needed.
Study NCT03002701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UNDERPIN-ICU program
Description: UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
Study NCT03591497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: As described in Experimental arm description.
Study NCT00920790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
Study NCT01736969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD047-023
Description: Experimental hydrogel
Study NCT01736969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predicate Device
Study NCT04166565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
Study NCT04166565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
Study NCT04166565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
Study NCT03855800 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood, stool, pancreatic juice and cyst fluid collection
Description: Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
Study NCT04166565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
Study NCT03458182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Added exercise
Description: After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
Study NCT03928067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNF + SAF
Description: Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
Study NCT03399825 — intervention group
Intervention type: DEVICE
Intervention: OCT-A
Description: optical coherence tomography angiography~Imaging with optical coherence tomography angiography
Study NCT04031755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Study NCT04031755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Study NCT02194699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT02029885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Therapy (Surround Sound)
Study NCT02029885 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Study NCT02245295 — intervention group
Intervention type: PROCEDURE
Intervention: Moderate Sedation for EBUS/TBNA
Description: EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
Study NCT02245295 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia for EBUS/TBNA
Description: EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
Study NCT02813681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-epidural SVD
Description: participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
Study NCT02813681 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: US sham- epidural SVD
Description: participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
Study NCT02813681 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spontaneous vaginal delivery without an Epidural
Description: Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
Study NCT02500706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
Study NCT02500706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
Study NCT02500706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
Study NCT02500706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
Study NCT03855800 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood, stool, pancreatic juice and cyst fluid collection
Description: Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
Study NCT01729806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01729806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01729806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04700891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Olfactory identification test
Description: Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function.
Study NCT00760734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low pressure hyperbaric oxygen therapy
Description: HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
Study NCT00760734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low pressure hyperbaric oxygen therapy
Description: HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
Study NCT03765788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg, s.c.
Description: Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
Study NCT03765788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
Study NCT03765788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
Study NCT03765788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
Study NCT01590303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
Study NCT01590303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
Study NCT03436056 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
Description: Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
Study NCT03436056 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)
Description: Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
Study NCT03436056 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose
Description: Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
Study NCT03436056 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
Study NCT00125515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: One arm receives 30 mg bid and the other arm receives receives 15mg bid
Study NCT00125515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
Study NCT00125515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
Study NCT03495921 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vigil
Description: Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
Study NCT03495921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
Study NCT03495921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.